CBAY
Cymabay Therapeutics
CBAY
CBAY
Delisted
CBAY was delisted on the 21st of March, 2024.
132 hedge funds and large institutions have $623M invested in Cymabay Therapeutics in 2018 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 40 increasing their positions, 28 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
132
Holders Change
+14
Holders Change %
+11.86%
% of All Funds
3.02%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
31
Increased
40
Reduced
28
Closed
17
Calls
$766K
Puts
$669K
Net Calls
+$97K
Net Calls Change
-$52K
Top Buyers
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$8.66M |
| 2 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$6.81M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$5.41M |
| 4 |
FI
Fosun International
Hong Kong,
China
|
+$5.15M |
| 5 |
BlackRock
New York
|
+$4.26M |
Top Sellers
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$17.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$10.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.03M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.54M |
| 5 |
OA
Omega Advisors
New York
|
-$5.06M |
